Drug Profile
Praluzatamab ravtansine - CytomX Therapeutics
Alternative Names: Anti-CD166-DM4-CX-2009; CD166 Probody Drug Conjugate; CX-2009Latest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator CytomX Therapeutics; ImmunoGen
- Developer CytomX Therapeutics
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Breast cancer; Solid tumours